Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Santarpia, Mariacarmela"'
Autor:
Spagnolo, Calogera Claudia, Ciappina, Giuliana, Giovannetti, Elisa, Squeri, Andrea, Granata, Barbara, Lazzari, Chiara, Pretelli, Giulia, Pasello, Giulia, Santarpia, Mariacarmela
Publikováno v:
Spagnolo, C C, Ciappina, G, Giovannetti, E, Squeri, A, Granata, B, Lazzari, C, Pretelli, G, Pasello, G & Santarpia, M 2023, ' Targeting MET in Non-Small Cell Lung Cancer (NSCLC) : A New Old Story? ', International Journal of Molecular Sciences, vol. 24, no. 12, 10119 . https://doi.org/10.3390/ijms241210119
In recent years, we have seen the development and approval for clinical use of an increasing number of therapeutic agents against actionable oncogenic drivers in metastatic non-small cell lung cancer (NSCLC). Among them, selective inhibitors, includi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10172::10e33886b5a458c9eb6a40be5f85db98
https://research.vumc.nl/en/publications/a73345c3-0e17-47a2-84b5-a94920e14e1b
https://research.vumc.nl/en/publications/a73345c3-0e17-47a2-84b5-a94920e14e1b
Autor:
Massafra,Marco, Passalacqua,Maria Ilenia, Gebbia,Vittorio, Macrì,Paolo, Lazzari,Chiara, Gregorc,Vanesa, Buda,Carmelo, Altavilla,Giuseppe, Santarpia,Mariacarmela
Publikováno v:
Biologics: Targets and Therapy.
Marco Massafra,1,* Maria Ilenia Passalacqua,1,* Vittorio Gebbia,2,3 Paolo Macrì,4 Chiara Lazzari,5 Vanesa Gregorc,5 Carmelo Buda,1 Giuseppe Altavilla,1 Mariacarmela Santarpia1 1Medical Oncology Unit, Department of Human Pathology âG.
Autor:
Dottore, Alessia, Ruggeri Rosa Maria, Massafra, Marco, Pettineo, Giuseppe, Garipoli, Claudia, Giuffrida, Giuseppe, Maisano, Carmelo, D'Aquino, Antonio, Santarpia, Mariacarmela, Altavilla, Giuseppe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3978::0d5be140f8025dfd3cd1d8049cde9cc3
http://hdl.handle.net/11570/3181730
http://hdl.handle.net/11570/3181730
Publikováno v:
International Journal of Cancer
KRAS is the most frequently mutated oncogene in non‐small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS muta
Autor:
Emanuela, Germanà, Umberto, Malapelle, Simone, Angela, Scarfi', Rosa, Ieni, Antonio, Riccardo, Smeraglio, Santarpia, Mariacarmela, Troncone, Giancarlo, Tuccari, Giovanni, Giuffre', Giuseppe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3978::f8df57e41736c8c1c3acf4fb9519a1e2
http://hdl.handle.net/11570/3134490
http://hdl.handle.net/11570/3134490
Publikováno v:
Cancer Biology & Medicine, Vol 12, Iss 2, Pp 74-78 (2015)
Cancer Biology & Medicine
Cancer Biology & Medicine
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Autor:
Santarpia,Mariacarmela, Liguori,Alessia, Karachaliou,Niki, Gonzalez-Cao,Maria, Daffinà ,Maria Grazia, D'Aveni,Alessandro, Marabello,Grazia, Altavilla,Giuseppe, Rosell,Rafael
Publikováno v:
Lung Cancer: Targets and Therapy.
Mariacarmela Santarpia,1 Alessia Liguori,1 Niki Karachaliou,2 Maria Gonzalez-Cao,3 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Giuseppe Altavilla,1 Rafael Rosell3–5 1Medical Oncology Unit, Department of Human Pathology “G. B
Autor:
Santarpia,Mariacarmela, Daffinà ,Maria Grazia, D'Aveni,Alessandro, Marabello,Grazia, Liguori,Alessia, Giovannetti,Elisa, Karachaliou,Niki, Gonzalez Cao,Maria, Rosell,Rafael, Altavilla,Giuseppe
Publikováno v:
Drug Design, Development and Therapy.
Mariacarmela Santarpia,1 Maria Grazia Daffinà,1 Alessandro D’Aveni,1 Grazia Marabello,1 Alessia Liguori,1 Elisa Giovannetti,2–4 Niki Karachaliou,5 Maria Gonzalez Cao,6 Rafael Rosell,7,8 Giuseppe Altavilla1 1Medical Oncology Unit, Department of H
Autor:
Rolfo, Christian, Caglevic, Christian, Santarpia, Mariacarmela, Araujo, Antonio, Giovannetti, Elisa, Diaz Gallardo, Carolina, Pauwels, Patrick, Mahave, Mauricio
Publikováno v:
Advances in experimental medicine and biology
Lung cancer is the leader malignancy worldwide accounting 1.5 millions of deaths every year. In the United States the 5 year-overall survival is less than 20% for all the newly diagnosed patients. Cisplatin-based cytotoxic chemotherapy for unresectab
Autor:
González Cao, María, Rodón, Jordi, Karachaliou, Niki, Sánchez, Jesús, Santarpia, Mariacarmela, Viteri, Santiago, Pilotto, Sara, Teixidó, Cristina, Riso, Aldo, Rosell, Rafael
Publikováno v:
Annals of translational medicine. 3(18)
Targeted therapy drugs are developed against specific molecular alterations on cancer cells. Because they are “targeted” to the tumor, these therapies are more effective and better tolerated than conventional therapies such as chemotherapy. In th